GlassScriptPhysician profile
Isabel C Kessler
NPI 1598229031
$485.89
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $272.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $177.00 | 2022 | |
| Abbvie INC. | $98.65 | 2021-2022 | |
| Csl Behring | $38.48 | 2022 | |
| Acadia Pharmaceuticals INC | $38.47 | 2021 | |
| Eisai INC. | $24.40 | 2021 | |
| Upsher-Smith Laboratories LLC | $21.31 | 2021 | |
| Sk Life Science, INC. | $19.77 | 2021 | |
| Medtronic, INC. | $19.21 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.41 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.18 | 2021 | |
| Genentech USA, INC. | $15.01 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.